Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) announced Wednesday that it has preliminary net revenue of approximately $93 million for its NURTEC ODT product in the second quarter of 2021.
During Q1, Biohaven Pharmaceutical's (NYSE:BHVN) reported sales totaled $43.82 million. Despite a 28.93% in earnings, the company posted a loss of $235.88 million. In Q4, Biohaven Pharmaceutical brought in $35.11 million in sales but lost $182.95 million in earnings.
Eli Lilly And Co (NYSE:LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical Holding Co Ltd’s (NYSE:BHVN) Nurtec…